Illumina long-term thesis unchanged despite Q4 negatives, says UBS

UBS analyst Daniel Brennan noted Illumina reported negative NovaSeq data in Q4, but said the long-term thesis remains intact. He said very large markets for Illumina and next-gen sequencing are just opening up, yielding a robust growth opportunity. The company’s demand elasticity remains intact, its financial position remains attractive, and the company remains in a dominant position, according to Brenna. He reiterated his Buy rating and lowered his price target to $350 from $370 on Illumina shares following the company’s quarterly report.

https://thefly.com/landingPageNews.php?id=2855823